Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,341 result(s) found. Displaying page 1,760 of 2,218.
    «« First « Previous 1756  1757  1758  1759  1760  1761  1762  1763  1764  Next» Last»»
    EudraCT Number: 2018-002699-42 Sponsor Protocol Number: DANBLOCK Start Date*: 2018-09-28
    Sponsor Name:Bispebjerg Frederiksberg Hospital
    Full Title: Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK)
    Medical condition: Myocardial infarction. We wish to test whether long-term treatment with betablocker (bisoprolol, carvedilol, metoprolol or nebivolol) leads to better prognosis than no treatment in patients sufferi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028595 Myocardial infarct LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004360-26 Sponsor Protocol Number: CLL16 Start Date*: 2021-08-24
    Sponsor Name:German CLL Study Group (University of Cologne)
    Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS...
    Medical condition: Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004914-79 Sponsor Protocol Number: CA017-003 Start Date*: 2016-10-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
    Medical condition: Advanced Malignant Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Completed) NO (Completed) FI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000782-36 Sponsor Protocol Number: AGO/2013/002 Start Date*: 2013-08-13
    Sponsor Name:Ghent University Hospital
    Full Title: Effect of TachoSil® on incidence of symptomatic and radiographic lymphoceles after extended pelvic lymph node dissection in prostate and bladder cancer.
    Medical condition: Patients with prostate cancer or bladder cancer, undergoing transperitoneal pelvic lymph node dissection.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10057890 Lymph node dissection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002373-59 Sponsor Protocol Number: 19-00153 Start Date*: 2020-12-22
    Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz
    Full Title: A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II).
    Medical condition: Malignant B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-000746-32 Sponsor Protocol Number: 5-HT_CFM Start Date*: 2008-04-23
    Sponsor Name:Karolinska Institutet
    Full Title: Validation of experimental pain models as translational for craniofacial myalgia with respect to the influence of 5-HT, glutamate, cortisol and estradiol level
    Medical condition: Patients with craniomandibular myalgia (CM), i.e. with pain in the masster muscle and a diagnosis of myofascial pain according to the RDC/TMD criteria, and healthy subjects of both sexes, over 18 y...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005625-78 Sponsor Protocol Number: FASTXP2013 Start Date*: 2013-06-24
    Sponsor Name:Karolinska Institutet
    Full Title: Food Allergy Surpression Therapy during protection with Xolair
    Medical condition:
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002573-62 Sponsor Protocol Number: ClinTrid-US-1201 Start Date*: 2012-10-12
    Sponsor Name:The Karolinska Institute, ClinTRID
    Full Title: Doppler quantitative evaluation and follow-up over 12 months in RA patients with moderate and high disease activity who are candidates for biologic add-on therapy with Adalimumab
    Medical condition: Rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000095-10 Sponsor Protocol Number: BATCP Start Date*: 2015-03-30
    Sponsor Name:Karolinska Institutet
    Full Title: Botulinum toxin-A as a treatment for chronic muscle-related pain in adults with spastic cerebral palsy: a randomized controlled trial.
    Medical condition: Spastic cerebral palsy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005005-20 Sponsor Protocol Number: 2014-005005-20 Start Date*: 2015-01-28
    Sponsor Name:Karolinska Institute
    Full Title: Karisma Pilot: A randomized, open pilot study to investigate the mammographic density reduction in healthy women ,within the Karma cohort, for two different doses of tamoxifen.
    Medical condition: A randomized, open pilot study to investigate the mammographic density reduction in healthy women ,within the Karma cohort, for two different doses of tamoxifen.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000882-22 Sponsor Protocol Number: KARISMAII Start Date*: 2016-07-11
    Sponsor Name:Karolinska Institute
    Full Title: Karisma II: A randomized, double blinded, six-armed placebo controlled study to imnvestigate optimal dose of tamoxifen with the most favourable side effect spectra and with density reduction non-in...
    Medical condition: The mammographic density reduction in healthy women, within the Karma cohort for five different doses of tamoxifen.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005715-32 Sponsor Protocol Number: SOCODIHF Start Date*: 2017-12-07
    Sponsor Name:Karolinska Institutet Stockholm, Sweden
    Full Title: SOdium-glucose CO-transporter inhibition in patients with Type 2 Diabetes and Ischemic Heart Failure (SOCODIHF)
    Medical condition: Patients with type 2 diabetes mellitus and heart failure of ischemic origin
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000158-21 Sponsor Protocol Number: 740220 Start Date*: 2017-04-13
    Sponsor Name:Karolinska Institutet
    Full Title: Ferroglycine Sulfate Absorption in patients with Heart Failure and Iron Deficency: an interventional before and after study.
    Medical condition: Chronic Heart Failure with Iron Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022977 Iron deficiency anemia, unspecified LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004548-35 Sponsor Protocol Number: 15081982 Start Date*: 2010-08-20
    Sponsor Name:Radboud university nijmegen medical centre
    Full Title: PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER
    Medical condition: Patients with metastatic clear cell renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002057-38 Sponsor Protocol Number: 64091742PCR2001 Start Date*: 2016-09-26
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
    Medical condition: mCRPC and DNA-repair anomalies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) DK (Prematurely Ended) NL (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003098-24 Sponsor Protocol Number: CLCZ696I12201 Start Date*: 2019-12-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardio...
    Medical condition: non-obstructive hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005990-29 Sponsor Protocol Number: ENGOT-OV64/NSGO-CTU-SOLERO Start Date*: 2021-12-14
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU)
    Full Title: An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer
    Medical condition: Patients with histologically diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer with radiologically or histologically confirmation of relapsed disease, and with known BRCA wi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) NO (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004414-35 Sponsor Protocol Number: IMPRESSNorway Start Date*: 2021-02-19
    Sponsor Name:Oslo University Hospital
    Full Title: Improving public cancer care by implementing precision medicine in Norway
    Medical condition: Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004446-29 Sponsor Protocol Number: LIBERAL-Trial Start Date*: 2017-10-30
    Sponsor Name:University Hospital Wuerzburg, Institution under public law, represented by the Medical Director
    Full Title: Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients
    Medical condition: Elderly patients (>= 70 years) undergoing intermediate- or high-risk non-cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    27.0 10022117 - Injury, poisoning and procedural complications 10048861 Anaemia postoperative PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002331-41 Sponsor Protocol Number: HaploMUDStudy Start Date*: 2019-09-27
    Sponsor Name:University Medical Center Hamburg - Eppendorf
    Full Title: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized Prospective European Trial
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1756  1757  1758  1759  1760  1761  1762  1763  1764  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 08:14:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA